Skip to main content

Translational Research Network in Prostate Cancer

Objective

The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).

The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.

Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:

1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.

2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.

3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.

We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.

Field of science

  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/prostate cancer

Call for proposal

H2020-MSCA-ITN-2016
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

UNIVERSITY OF GLASGOW
Address
University Avenue
G12 8QQ Glasgow
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 273 287,88

Participants (11)

UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
EU contribution
€ 273 287,88
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
Activity type
Higher or Secondary Education Establishments
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU contribution
€ 204 965,91
Address
University Road Lanyon Building
BT7 1NN Belfast
Activity type
Higher or Secondary Education Establishments
TURUN YLIOPISTO
Finland
EU contribution
€ 269 145,36
Address
Yliopistonmaki
20014 Turku
Activity type
Higher or Secondary Education Establishments
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 255 374,28
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
MOSAIQUES DIAGNOSTICS GMBH

Participation ended

Germany
EU contribution
€ 0
Address
Rotenburger Strasse 20
30659 Hannover
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 242 386,92
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
TAMPEREEN YLIOPISTO

Participation ended

Finland
EU contribution
€ 0
Address
Kalevantie 4
33014 Tampere
Activity type
Higher or Secondary Education Establishments
TAMPEREEN KORKEAKOULUSAATIO SR
Finland
EU contribution
€ 269 145,36
Address
Kalevantie 4
33100 Tampere
Activity type
Higher or Secondary Education Establishments
GenomeScan B.V.
Netherlands
EU contribution
€ 319 217,85
Address
Plesmanlaan 1D
2333 BZ Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALMAC DIAGNOSTIC SERVICES LIMITED
United Kingdom
EU contribution
€ 273 287,88
Address
Seagoe Industrial Estate 20
BT63 5QD Craigavon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NUMARES AG
Germany
EU contribution
€ 249 216,48
Address
Am Biopark 9
93053 Regensburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Partners (6)

UNIVERSITY OF STRATHCLYDE
United Kingdom
Address
Richmond Street 16
G1 1XQ Glasgow
Activity type
Higher or Secondary Education Establishments
Prostate Cancer UK
United Kingdom
Address
Fourth Floor Counting House
SE1 2QN London
Activity type
Other
HELSINGIN YLIOPISTO
Finland
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
European Association of Urology
Switzerland
Address
Amthausgasse 6
3011 Bern Bern
Activity type
Research Organisations
Carver Wilde Communications
United Kingdom
Address
20 Mortlake High Street
SW14 8JN London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CANCER RESEARCH UK LBG
United Kingdom
Address
St John Street 407 Angel Building
EC1V 4AD London
Activity type
Research Organisations